CA-SERVICENOW,-INC.
15.4.2020 15:32:06 CEST | Business Wire | Press release
ServiceNow (NYSE: NOW), the leading digital workflow company that makes work, work better for people, is committing to protect the jobs of its 11,000-plus global workforce through 2020 despite the economic uncertainty of the COVID-19 pandemic. The company also expects to keep hiring for new jobs worldwide this year. In addition, ServiceNow expects to continue to protect the jobs and salaries of several hundred support staff and contractors who are not working while ServiceNow’s offices remain closed.
“We want our employees focused on supporting our customers, not worried about their own jobs,” said Bill McDermott, ServiceNow’s CEO. “We are committed to no layoffs for 2020. We are continuing to hire worldwide.”
“We are grateful to be in this position,” McDermott continued. “Keeping our company strong means we can help our customers succeed. Supporting our customers, we can help get the U.S. and global economy working again. More than ever, companies see that creating great workflow-designed experiences help protect revenue and growth, provide business continuity and drive productivity. These are the priorities for every company now. We are all in this together.”
ServiceNow has continued to hire and onboard new employees throughout the COVID-19 pandemic. The company expects to create and fill more than 1,000 new jobs in the U.S., and more worldwide, by the end of 2020. Additionally, this summer the company will welcome approximately 360 college interns from around the world to work across its business. As a digital workflow company, ServiceNow has been able to quickly pivot to a digital internship program, maintaining the ability to provide college interns valuable career experience, even if employees continue to operate in a work-from-home environment. ServiceNow’s employees worldwide have been working from home since mid-March and expect to continue to do so until June 1.
Caroline Parkinson, a 2021 expected graduate of the University of Michigan who will join ServiceNow’s internship program this summer, said: “ServiceNow saved my summer. Without their digital intern program, I would have had to scramble to find a new summer job. Knowing that ServiceNow is determined to make my internship as enriching as possible during this uncertain time reaffirms my decision to join this company.”
Additionally, ServiceNow, along with Accenture, Lincoln Financial Group, and Verizon, this week announced People+Work Connect , a collaborative online employer-to-employer initiative that will bring together companies with workforces laid off or furloughed due to COVID-19 with those in urgent need of workers. More than 800 ServiceNow jobs will be posted through this collaborative effort. At no charge for employers to join and participate, the initiative is intended to help shorten the complex, lengthy cycle of finding new employment. For more information, visit: https://peopleworkconnect.accenture.com/welcome .
Helping our Customers Respond to COVID-19
ServiceNow is continuing to work aggressively to support its customers during this challenging time, including helping local, state and federal agencies better manage and coordinate emergency response efforts by utilizing ServiceNow’s digital workflow platform technology and no-charge COVID-19 emergency response applications.
Washington State’s Department of Health, a ServiceNow customer, initially created the Emergency Response Operations app on the Now Platform to manage their own response to COVID-19. Working with ServiceNow, the Department of Health has made the app available to all government entities at no charge.
In addition to the State of Washington’s Emergency Response Operations app, ServiceNow recently developed and introduced three, no-charge community apps: Emergency Outreach App, Emergency Self Report App and Emergency Exposure Management app. These community apps are part of a broader Customer Care Plan launched by ServiceNow in March to support its customers as they focus on maintaining business operations during the COVID-19 pandemic.
Examples of organizations leveraging ServiceNow to support their COVID-19 efforts include:
- The City of Los Angeles , which was able to implement drive-through COVID-19 testing using the Now Platform. Within 48 hours of deployment, the City pushed their portal live to 16 million citizens who can now research and verify symptoms, schedule an appointment and choose a drive-through testing location.
- The Calgary Catholic School District , which used the Now Platform to enable staff with links to critical information for a seamless, rapid transition from teaching in the classroom to educating from home. This continued student learning was made possible because of the simplified employee experience made available to their teacher.
- A US retail company , that was able to rapidly respond to the influx of human resources cases for emergency paid leave requests due to COVID-19 by using the Now Platform. Within 96 hours, a mobile application was built and deployed to 330,000 employees globally.
- A large City in the U.S. , which deployed an application on the Now Platform to assist 1.8 million of its citizens in need of food and distribution of other necessities during the COVID-19 pandemic.
“We deeply believe that technology should be in the service of people, and right now that means our responsibility is to help flatten the curve and aid other global organizations in continuing their own valuable work, employment and growth of their workforces,” McDermott said. “ServiceNow is committed to relentless innovation and protecting and creating jobs, to help us all emerge from this pandemic as a stronger community.”
More information about ServiceNow’s customer care plan, including accessing the community apps, can be found at servicenow.com/crisisresponse .
ServiceNow and its employees also have committed $1.5 million in cash donations to help COVID-19 response efforts. ServiceNow will make $1.225 million in corporate grants to the United Nations Foundation; the Centers for Disease Control Foundation; the NYC Mayor’s COVID-19 Emergency Relief Fund; the Silicon Valley Community Foundation COVID-19 Coronavirus Response Funds; and Second Harvest of Silicon Valley. Employee matching gift campaigns will raise additional funds to benefit non-profits in the local communities where our employees live and work.
Forward-Looking Statements
This press release contains forward‑looking statements relating to ServiceNow’s headcount, hiring and workforce expectations and plans. Such forward‑looking statements include, but are not limited to, statements that contain words such as expects, intends, aims or similar words conveying that the information is not historical fact. These statements reflect the current beliefs of ServiceNow and are based on current information available to ServiceNow as of the date hereof. Forward‑looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual outcomes and results to differ materially from those expected or implied by the forward‑looking statements. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our outcomes and results could differ materially from the those expressed or implied by the forward-looking statements ServiceNow makes. Factors that may cause actual outcomes and results to differ materially from those in any forward-looking statements include, without limitation, changes to global economic conditions and changes in the severity of the COVID-19 pandemic and its impact on our customers, partners or vendors. ServiceNow undertakes no obligation, and does not intend, to update these forward-looking statements after the date on which they are made.
About ServiceNow
ServiceNow (NYSE: NOW) is making the world of work, work better for people. Our cloud‑based platform and solutions deliver digital workflows that create great experiences and unlock productivity for employees and the enterprise. For more information, visit: www.servicenow.com .
© 2020 ServiceNow, Inc. All rights reserved. ServiceNow, the ServiceNow logo, Now, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries. Other company names, product names, and logos may be trademarks of the respective companies with which they are associated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200415005206/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
